Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Format: Artigo
Jezik:Russo
Izdano: ABV-press 2014-11-01
Serija:Onkourologiâ
Teme:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Online pristup:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items